Cure8 research brief
This preclinical study identifies benzoylpaeoniflorin (BPF) as a compound that improved experimental colitis in mice by changing macrophage polarization via the RNF31–DPEP2–NF-κB pathway. It highlights a possible therapeutic target and mechanistic biomarker path relevant to UC drug discovery.
Researchers in IBD immunology and drug discovery, clinicians following preclinical UC research, and translational scientists working on macrophage-targeted therapies.
This study (abstract) reports that benzoylpaeoniflorin (BPF) reduced colitis severity in a mouse DSS model and shifted macrophages from an M1 to an M2 phenotype.
The authors used cell (RAW264.7) and mouse experiments and implicate a molecular mechanism: BPF appears to prevent RNF31-mediated ubiquitination and degradation of DPEP2, which limits NF-κB activation and promotes M2 polarization. Knockdown of DPEP2 or overexpression of RNF31 reversed BPF’s effects, and depleting macrophages removed BPF’s benefit in mice.
The work is presented as preclinical mechanistic research in an experimental mouse model and cultured macrophages; it does not report human clinical data. It suggests a potential anti-inflammatory pathway (RNF31–DPEP2–NF-κB) and identifies BPF as a candidate compound that modulates macrophage polarization and mucosal barrier damage in UC models.
Results are from mouse DSS colitis and in vitro macrophage experiments (abstract-level summary). This is mechanistic, preclinical research and does not demonstrate safety or efficacy in humans.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.
The study describes new small molecules that target IL‑6 and NF‑κB and showed anti-inflammatory effects in laboratory and mouse colitis models, signaling a potential early-stage drug-discovery direction relevant to IBD...
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined...
